Biotechnology company · VRTX

Vertex Pharmaceuticals
clinical trial
pipeline

Registry checked

Published

Povetacicept is linked to 6 distinct active studies, with 2 Phase 2, 4 Phase 3. Suzetrigine is linked to 4 distinct active studies, with 3 Phase 3, 1 Phase 4.

Phase 3 study NCT06696443 in Diabetic Peripheral Neuropathic Pain lists estimated primary completion on 25 January 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

34active trials
as lead sponsor
  • Phase 16
  • Phase 27
  • Phase 319
  • Phase 41
  • Phase not recorded1

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

169 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

NCT07868926 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-061000011
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-101000011
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-161010021
2026-10-170000221
2026-10-180000000
2026-10-190000000
2026-10-201100132
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-282020042
2026-10-291010021
2026-10-300000000
2026-10-311000011
Type totals81403169 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Povetacicept

Canonical investigational asset

6
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Immunoglobulin A Nephropathy · Lupus Nephritis
Next primary completion
Not reported
Open drug

Suzetrigine

journavx

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 33
  • Phase 41
  • Phase not recorded0
Studied condition
Diabetic Peripheral Neuropathic Pain · Pain
Next primary completion
25 January 2027 · estimated
Open drug

Exagamglogene Autotemcel

Canonical investigational asset

4
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Beta-Thalassemia · Genetic Diseases, Inborn · Hematologic Diseases
Next primary completion
06 June 2027 · estimated
Open drug

VNZ/TEZ/D-IVA

Alyftrek

3
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Cystic Fibrosis
Next primary completion
Not reported
Open drug

ELX/TEZ/IVA

Kaftrio · Trikafta

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Cystic Fibrosis
Next primary completion
06 April 2027 · estimated
Open drug

Zimislecel

Canonical investigational asset

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Diabetes Mellitus, Type 1 · Impaired Hypoglycemic Awareness · Kidney Transplant
Next primary completion
Not reported
Open drug

32 of 34 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 32 of 34 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Vertex Pharmaceuticals trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Suzetrigine

NCT06696443

Phase 3 · Active, not recruiting

Trial source and qualifications

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 18 Dec 2024 · actual
    Primary completion: 25 Jan 2027 · estimated
    Study completion: 25 Jan 2027 · estimated

    2021202220232024202520262027202820292030
    Galileo
    VX-670

    NCT06185764

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    5 candidate observations · 2 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-08-21 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-08-21 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 20 Feb 2024 · actual
    Primary completion: 02 Feb 2027 · estimated
    Study completion: 02 Feb 2027 · estimated

    2021202220232024202520262027202820292030
    A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
    VX-264

    NCT05791201

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 16 May 2023 · actual
      Primary completion: 12 Mar 2027 · estimated
      Study completion: 12 Mar 2027 · estimated

      2021202220232024202520262027202820292030
      Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
      VX-993

      NCT06619860

      Phase 2 · Recruiting

      Trial source and qualifications

      Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 18 Oct 2024 · actual
        Primary completion: 25 Mar 2027 · estimated
        Study completion: 22 Apr 2027 · estimated

        2021202220232024202520262027202820292030
        Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
        ELX/TEZ/IVA

        NCT05331183

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 23 Nov 2022 · actual
          Primary completion: 06 Apr 2027 · estimated
          Study completion: 06 Apr 2027 · estimated

          2021202220232024202520262027202820292030
          Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
          Suzetrigine

          NCT07231419

          Phase 3 · Recruiting

          Trial source and qualifications

          Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 21 Nov 2025 · actual
            Primary completion: 06 Apr 2027 · estimated
            Study completion: 06 Apr 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 23 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 2 past estimates, 1 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            8

            active trials in Renal & Urology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Renal & Urology8 trials
            • Respiratory8 trials
            • Metabolic/Endocrine/Nutrition7 trials
            • Haematology4 trials
            • Neurology2 trials
            • Immunology & Inflammation1 trials
            • Pain & Musculoskeletal1 trials
            • Unmapped3 trials
            • Healthy volunteers0 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies

            No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 275 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Vertex Pharmaceuticals Incorporated. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            275 distinct registry candidates produced 275 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            262 scoped records have indexed enrichment and 13 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T03:53:33.503Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 9854481b2118481899ab9871aa50acf90b0bb57b9f5388e7467c344f19fb1108.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 275 mapped lead-sponsored clinical studies across all statuses. 262 have indexed enrichment, 13 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.